Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| macrophage | 20 studies | 32% ± 20% | |
| myeloid cell | 7 studies | 46% ± 23% | |
| monocyte | 6 studies | 32% ± 14% | |
| alveolar macrophage | 3 studies | 18% ± 1% | |
| microglial cell | 3 studies | 24% ± 5% |
Insufficient scRNA-seq data for expression of PLA2G7 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| prostate | 98% | 393.09 | 240 / 245 | 99% | 128.20 | 498 / 502 |
| thymus | 100% | 715.01 | 652 / 653 | 89% | 22.47 | 537 / 605 |
| lung | 98% | 684.07 | 567 / 578 | 90% | 23.55 | 1040 / 1155 |
| breast | 78% | 204.54 | 358 / 459 | 72% | 14.70 | 803 / 1118 |
| brain | 85% | 140.39 | 2240 / 2642 | 59% | 8.05 | 415 / 705 |
| intestine | 53% | 137.18 | 508 / 966 | 77% | 14.52 | 405 / 527 |
| skin | 63% | 91.24 | 1146 / 1809 | 65% | 14.99 | 306 / 472 |
| bladder | 52% | 68.05 | 11 / 21 | 69% | 13.21 | 349 / 504 |
| ovary | 60% | 90.66 | 108 / 180 | 51% | 6.48 | 221 / 430 |
| stomach | 25% | 27.18 | 90 / 359 | 83% | 19.70 | 238 / 286 |
| adrenal gland | 78% | 117.71 | 201 / 258 | 22% | 3.22 | 51 / 230 |
| liver | 50% | 61.21 | 113 / 226 | 50% | 9.66 | 203 / 406 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 127.51 | 29 / 29 |
| spleen | 100% | 1395.06 | 241 / 241 | 0% | 0 | 0 / 0 |
| uterus | 21% | 43.79 | 35 / 170 | 74% | 13.25 | 338 / 459 |
| pancreas | 13% | 15.70 | 42 / 328 | 79% | 17.12 | 140 / 178 |
| esophagus | 9% | 9.55 | 132 / 1445 | 75% | 13.21 | 137 / 183 |
| kidney | 18% | 20.38 | 16 / 89 | 65% | 12.82 | 589 / 901 |
| tonsil | 0% | 0 | 0 / 0 | 82% | 19.42 | 37 / 45 |
| adipose | 82% | 339.84 | 989 / 1204 | 0% | 0 | 0 / 0 |
| peripheral blood | 73% | 166.85 | 675 / 929 | 0% | 0 | 0 / 0 |
| blood vessel | 30% | 65.16 | 396 / 1335 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 24% | 3.37 | 19 / 80 |
| heart | 13% | 13.31 | 110 / 861 | 0% | 0 | 0 / 0 |
| muscle | 3% | 2.79 | 28 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0062234 | Biological process | platelet activating factor catabolic process |
| GO_0016486 | Biological process | peptide hormone processing |
| GO_0090026 | Biological process | positive regulation of monocyte chemotaxis |
| GO_0034638 | Biological process | phosphatidylcholine catabolic process |
| GO_0034374 | Biological process | low-density lipoprotein particle remodeling |
| GO_0050729 | Biological process | positive regulation of inflammatory response |
| GO_0034441 | Biological process | plasma lipoprotein particle oxidation |
| GO_0034440 | Biological process | lipid oxidation |
| GO_0046469 | Biological process | platelet activating factor metabolic process |
| GO_0034362 | Cellular component | low-density lipoprotein particle |
| GO_0005576 | Cellular component | extracellular region |
| GO_0034364 | Cellular component | high-density lipoprotein particle |
| GO_0047499 | Molecular function | calcium-independent phospholipase A2 activity |
| GO_0003847 | Molecular function | 1-alkyl-2-acetylglycerophosphocholine esterase activity |
| GO_0016788 | Molecular function | hydrolase activity, acting on ester bonds |
| GO_0005543 | Molecular function | phospholipid binding |
| Gene name | PLA2G7 |
| Protein name | Platelet-activating factor acetylhydrolase (PAF acetylhydrolase) (EC 3.1.1.47) (1-alkyl-2-acetylglycerophosphocholine esterase) (2-acetyl-1-alkylglycerophosphocholine esterase) (Group-VIIA phospholipase A2) (gVIIA-PLA2) (LDL-associated phospholipase A2) (LDL-PLA(2)) (PAF 2-acylhydrolase) |
| Synonyms | PAFAH |
| Description | FUNCTION: Lipoprotein-associated calcium-independent phospholipase A2 involved in phospholipid catabolism during inflammatory and oxidative stress response . At the lipid-aqueous interface, hydrolyzes the ester bond of fatty acyl group attached at sn-2 position of phospholipids (phospholipase A2 activity) . Specifically targets phospholipids with a short-chain fatty acyl group at sn-2 position . Can hydrolyze phospholipids with long fatty acyl chains, only if they carry oxidized functional groups . Hydrolyzes and inactivates platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine), a potent pro-inflammatory signaling lipid that acts through PTAFR on various innate immune cells . Hydrolyzes oxidatively truncated phospholipids carrying an aldehyde group at omega position, preventing their accumulation in low-density lipoprotein (LDL) particles and uncontrolled pro-inflammatory effects . As part of high-density lipoprotein (HDL) particles, can hydrolyze phospholipids having long-chain fatty acyl hydroperoxides at sn-2 position and protect against potential accumulation of these oxylipins in the vascular wall . Catalyzes the release from membrane phospholipids of F2-isoprostanes, lipid biomarkers of cellular oxidative damage . . |
| Accessions | Q13093 ENST00000537365.1 ENST00000274793.12 |
